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Abstract 
Genetic determinants that are associated with preeclampsia still remain elusive 
nowadays, which might have resulted from limited understanding of the underlying 
pathogenesis mechanisms and the fetal contributions. By using genome-wide association 
study approach, we identified 2 candidate copy number deletions of the highest odds ratio 
ranking on chromosome 1 and 19, from 283 US white babies born by the mothers with 
preeclampsia. Based on the molecular and biological functions of the genes entailed the 
deleted regions, which contain CTSK, ARNT, and ACTN4, we proposed that these two 
candidate genomic deletions might be associated with preeclampsia. In a further attempt to 
replicate our findings in an independent dataset that contains 1200 white European babies, 
we did not find genes matched with our highest ranking candidates; however, one specific 
gene RYR1 deletion was identified in both datasets, and it can also be found in an 
established genetic database of preeclampsia genes. Our study was aimed to better 
understand the etiology of preeclampsia and in hopes to develop better screening tools 
based on genetic variants carried by the predisposed mother or fetus in the coming future. 
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Introduction 
Among pregnant women in the US, approximately 6-8% develop high blood pressure annually; 
the underlying hypertensive disorders are the top cause of maternal death during pregnancy
1
. 
Preeclampsia (PE) is one of the serious hypertensive disorders that are characterized by newly 
onset hypertension and proteinuria, which usually starts after 20 weeks of gestation, and occurs 
in about 5-8% of pregnancies worldwide
2
. When preeclampsia further progresses to eclampsia 
(seizure), the condition is highly dangerous and can be fatal to both mother and the baby. There 
is still no way to predict and prevent preeclampsia, and the only known cure so far is delivery of 
the baby and complete removal of the conception products, which also turns out to be the leading 
cause of preterm birth nowadays
3
. 
Preeclampsia has been shown in several studies with familial heredity
4-6
. However, the 
underlying genetic contributors remained elusive, and how these vary among racial groups is 
poorly understood. A number of candidate genes that have been indicated in the pathogenesis 
pathways involved in preeclampsia, including those related to immune dysfunction
7
, placenta 
ischemia, hypoxia or oxidative stress
8, 9
. Even though many candidate gene approach studies 
have been performed, the findings are inconclusive
10
, probably because of an still incomplete 
understanding of the underlying biological mechanisms involved in preeclampsia pathogenesis 
pathways to date
11
. Moreover, genome-wide association studies today mainly focus on single 
nucleotide polymorphisms (SNPs), which are the most frequent point mutations but only 
represented one part in the complicated genetic variations in associated with diverse diseases. 
Considerations that are specifically in the maternal genetic contributions but limited studies from 
the fetus side created barriers in understanding of preeclampsia heritability as well. There is now 
accumulated evidence from both epidemiological and genetic studies suggest a fetal role in the 
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etiology of preeclampsia
5, 6
; family study models also pointed out fetal determinants in 
susceptibility to preeclampsia
7, 12
. A large epidemiological study from Sweden unraveled role of 
genes expressed by the fetus in preeclampsia
13
. In the results they concluded that while 35% of 
the genetic variability in preeclampsia was attributable to maternal genetics alone, 20% could be 
attributed to fetal genetics alone, with the remainder unaccounted for. Nevertheless, we are still 
lacking published candidate gene association studies that have examined the role of specific fetal 
genetic variants on risk of preeclampsia. 
DNA structural variation—the copy number variations (CNVs)— is responsible for human 
evolution and is crucial for creating genetic diversity between individuals
14
. Although copy 
number variations are less common than SNP point mutations, the structural variation can lead to 
larger functional effects and make it susceptible to disease traits. Copy number variations 
involved deletions or duplications at distinct regions on the genome. They can functionally alter 
gene rearrangement by several mechanisms, including gene interruption, gene fusion, or 
alteration at the regulatory regions, which may lead to dose-sensitive genomic disorders. Several 
diseases have been found to be associated with copy number variations, such as sporadic 
chromosomal microdeletion Prader-Willi and DiGeorge syndromes
15
, and therefore copy number 
variations might be the missing puzzle that can help us dissecting the complex heritability of 
preeclampsia. 
Genome-wide association study (GWAS) is a hypothesis-free approach for uncovering the 
genetics of preeclampsia. Built upon our preliminary genome-wide study of maternal copy 
number variants in associated with preeclampsia
16
, our current study is conducted to identify 
potential fetal SNPs and copy number variations that are associated with preeclampsia in the 
mother using a case-control study design. 
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Materials and Methods 
Ethics statement 
We received approval from the University of Iowa Institutional Review Board and the Yale 
University Human Investigation Committee. 
Study population 
In order to maintain homogeneity in the preeclampsia phenotype, all of the children enrolled 
in our study were delivered by white Caucasian mothers of primiparous, without history of 
pre-existing hypertension, and delivered singleton live births. The mothers of the children were 
originally recruited for the Study of Pregnancy Hypertension in Iowa (SOPHIA), which was a 
case-control approach designed to examine the effects of maternal-fetal HLA sharing on risk of 
preeclampsia. These mothers were initially identified for the SOPHIA study through birth 
certificates provided by the Iowa Department of Public Health within 9 months of delivery, from 
August 2002 to May 2005. All mothers who were recorded positive on the birth certificate for 
pregnancy-induced hypertension or eclampsia were considered potential mothers of the cases, 
and a random sample of the mothers who were recorded negative were considered as potential 
mothers of the controls. Those who consented were further determined for initial eligibility. For 
both cases and controls, exclusion criteria included mothers’ age less than 18 years at delivery; 
non-English-speaking; history of an autoimmune disease (systemic lupus erythematosus, type 1 
diabetes mellitus, rheumatoid arthritis, etc.); recurrent spontaneous abortion ( more than 3 
sequential pregnancy losses); chronic hypertension; multiplegestation; major congenital 
anomalies; and infant death. Mothers who met initial eligibility criteria were invited to 
participate in the SOPHIA study and asked to complete an extensive telephone interview 
collecting information on family history of cardiovascular and renal diseases and preeclampsia, 
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and a detailed sexual history with the children’s father. A package containing buccal cell 
collection kits for the mother and her child, the medical record release forms and consent forms 
were mailed to the mothers, and they were asked to return the signed forms with buccal cell 
samples as soon as possible in the pre-paid postage envelope. DNA was extracted from the 
buccal samples and stored for analysis. Medical records were abstracted using a structured 
abstraction form collecting detailed information on blood pressure and urinary protein values 
during the prenatal, intrapartum, and immediate postpartum periods, along with information on 
potential exclusion criteria (diabetes, SLE, preexisting hypertension, etc.) for both mothers of 
cases and controls. To identify cases’ mothers, preeclampsia was defined according to the 
National Heart, Lung and Blood Institute (NHLBI) guidelines. Based on chart review, 288 study 
subjects, including 183 children of preeclamptic mothers and 105 children of non-preeclamptic 
mothers met the strict case and control criteria (Figure 1). Regarding to replicating our findings 
discovered in the SOPHIA study, we used white European subjects from the HAPO 
(Hyperglycemia and Adverse Pregnancy Outcome) study as to confirm our results. Detailed PE 
phenotypic definition and how we drawn our eligible study subjects (Figure 7) have been 
described in our previous publication
17
. 
Definition of preeclampsia 
Criteria of preeclampsia were defined by the National Heart, Lung and Blood Institute 
(NHLBI) guidelines. The criteria required: 1) newly onset hypertension (>140mmHg systolic or 
>90mmHg diastolic on two or more occasions at least six hours apart beginning after the 20
th
 
week of gestation; 2) accompanied with proteinuria, defined as urinary protein concentrations of 
30mg/dL or greater (equivalent to dipstick value of 1+ from two or more specimens collected at 
least four hours apart, or one or more urinary dipstick values of 2+ near the end or pregnancy, or 
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one or more catheterized dipstick values of 1+ during delivery hospitalization, or 24-hour urine 
collection with protein of ≧300mg. We excluded those children whose mothers for whom 
pre-existing hypertension could not be ruled out (ie. no readings available prior to 20
th
 weeks of 
gestation; medical charts indicating chronic hypertension in the patient); or whom only met 
partial criteria for preeclampsia (pregnancy-induced hypertension; proteinuria without 
hypertension); or whom had incomplete information so a definitive diagnosis could not be made. 
For those mothers of the control children, status was defined as a healthy, term delivery 
without evidence of maternal high blood pressure in the prenatal, intrapartum, or postpartum 
periods, no chronic hypertension, and no proteinuria (1+ on dipstick on two or more occasions). 
GWAS genotyping 
DNA samples, which previously isolated from buccal cells and stored at -20°C, were arrayed 
on 96-well plates, 1µg of DNA at 50ng/µL, submitted to the Yale Center for Genome Analysis 
for processing, using the Illumina Human OmniExpress microarray for a total genetic probes of 
731,442 on each chip. 
SNP analysis 
PLINK
18
 analysis toolset was applied for genetic marker quality control. We first excluded 
those individuals with genotyping call rate lower than 95% (n= 2 cases and 3 controls). SNPs 
were next examined and removed if they met any of the following criteria: 1) not having a 
genotyping call rate of 98% in either the cases or controls; 2) minor allele frequency (MAF) was 
less than 2%; 3) violation of the Hardy Weinberg Equilibrium (HWE) as p-values less than 1 x 
10
-7
. Q-Q plot showed no evidence of population stratification (no significant deviation, data not 
shown). Finally we had 283 study subjects (181 cases and 102 controls) and 647,382 SNPs to 
carry out the association analysis. Individual SNP was tested for both allelic and genotypic 
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associations by calculating Fisher’s exact p-values and using a strict Bonferroni-corrected 
genome-wide significant threshold at 7.72 × 10
-8
 (α = 0.05/647,382).  
Detection of copy number variants 
We applied three algorithms to insure higher quality of CNV calls (Figure 2). The 
PennCNV
19
(June 16, 2011 version), QuantiSNP
20
(version 2.3 beta) and GNOSIS (bundled in 
CNVision
21
 version 1.73) were used for CNV calls. Hidden Markov model based transitional 
probabilities were behind PennCNV and QuantiSNP algorithms that integrated log R ratio (LRR: 
a measure of total signal intensity of probes) and B allele frequency (BAF: a measure of relative 
intensity ratio of allelic probes) to infer CNV calls for individual genotyping sample. GNOSIS 
implements a continuous distribution function in sliding windows along the chromosomes to 
detect CNVs by using log R ratio and B allele frequency as well. Detection algorithms’ 
command lines were run under default settings for Illumina HumanOmniExpress-12 v1.1 B 
microarray; LRR and BAF raw fluorescent intensities were generated and exported from 
Illumina GenomeStudio software.  
The large number of CNV calls may reflect low DNA sample quality and false positive 
discovery
22
, therefore stringent quality control criteria are essential to maintain valid CNV calls. 
A single CNV might be detected multiple times due to fragmentation
23
, so we excluded those 
CNVs called by less than ten consecutive SNP or CNV probes first, as PennCNV suggested 
default CNV call QC criterion. We then log10-transformed the right-skewed distribution sample 
calls for each algorithm to correct non-normality. A study subject was considered to have failed 
CNV calls quality control and removed from further analysis (n = 7 cases and 5 controls) if 
he/she had an extremely large number of CNV calls, defined as having CNV calls greater than 
mean+3SD of the log10-transformed number of calls, presented in at least one of the three 
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algorithms. 
CNVision
24
 was used to analyze the merged CNV calls from PennCNV, QuantiSNP and 
GNOSIS. The merge function of CNVision combined CNV calls made by all three algorithms 
that had overlaps of ≥1 base pair and determined the percentage of call overlaps from specific 
algorithms. Merged CNV calls were excluded (n = 43,172) if one of the following conditions 
were met: 1) both deletion and amplification calls were made concurrently by different 
algorithms at the same overlap region; 2) <50% overlap between two algorithms and <25% 
overlap among three algorithms (Figure 3). 
Prioritization of copy number variants 
The recurrent function of CNVision screened copy number varied regions to extract those 
overlaps across our study subjects that were presented more frequently in the cases, and those 
overlapped regions containing less than five consecutive SNP or CNV probes were excluded 
along the process (Figure 3). We used a subjective prioritization strategy to further generate 
targeted CNV regions that were mostly enriched among cases: CNVs with odds ratios ≥ 2.25 
comparing children of preeclamptic mothers to children of non-preeclamptic mothers, or CNVs 
called in ≥3 cases but 0 in controls were then selected as candidates. Recurrent regions 
overlapping centromeric (±100kb) and telomeric (±500kb within the start or end region of a 
chromosome) regions were removed by using PennCNV bundled filtering script. We also 
checked with public available online databases to exclude non-unique copy number 
polymorphisms that are present in the general and healthy population. (Database of Genomic 
Variants: http://dgv.tcag.ca/dgv/app/home; The Copy Number Variation Project: 
http://cnv.chop.edu). 
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Results 
SNP Association 
A total of 283 genotyped study subjects (181 children of PE case mothers and 102 children of 
control mothers) passed the default quality control call rate threshold (≧95%), with the overall 
sample call rate reaching 99.94%. No SNPs surpassed the Bonferroni-corrected genome-wide 
significant threshold of 7.72x10
-8
 for the Fisher’s exact genotypic or allelic tests. The top 2 SNP 
candidates had a genotypic p-value less than 10
-5
 (Table 1). 
CNV Detection  
After merging CNV calls from all three CNV calling algorithms by using CNVision, a total of 
4,388 overlapped CNVs across genome among 174 children of PE case mothers and 97 children 
of control mothers met initial inclusion criteria. The length of these CNVs ranged from 24 bp to 
24 Mb with an average of 65 kb. Of these CNVs, 3,334 showed deletions (including 
homozygous and heterozygous deletions), and 1,054 were duplications. The CNVs were further 
screened to extract those overlaps across our study subjects that were mostly enriched among the 
cases, and those overlapped regions containing less than five consecutive SNP or CNV probes 
were excluded along the process; 608 deleted regions and 279 duplicated regions were then 
identified. 
Among the 608 deleted regions, 25 candidates surpassed odds ratio ≥ 2.25 comparing children 
of preeclamptic mothers to children of non-preeclamptic mothers, or CNVs called in ≥3 cases 
but 0 in controls, as described in the method section; correspondingly, 10 copy-number 
duplicated regions stood out to be candidates. We confirmed these candidate regions with the 
public available copy number variation databases online (http://cnv.chop.edu; 
http://dgv.tcag.ca/dgv/app/home) to exclude non-unique copy number polymorphisms that were 
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present in the general and healthy population
25
. Of the 25 deleted regions, 20 were left to be 
unique or not yet identified rare or low frequency CNVs; of the 10 duplicated regions, only 4 
were left to be unique CNVs (Table 2). 
Since loss of function of the protein products by homozygous or heterozygous deletions of 
certain genes are more frequent and severe than gains of function by slightly duplicated copies of 
the genes
26, 27
, we thus made deletions as a prioritized resource for exploring the genetic and 
biological basis of PE phenotypic variation. Of the 20 deleted regions, we discovered two 
interesting regions on chromosome 1q21.2 and 19q13.2 with the highest odds ratio rankings, 
containing ARNT, CTSK and ACTN4 annotated genes. Based on the molecular and biological 
regulatory functions of these genes, we proposed their associations with preeclampsia 
pathogenesis (Table 3). 
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Table 1 Association (p-value) of the top 2 SNP candidates with children of preeclampic 
mothers
a 
SNP
b
 Minor allele 
frequency (%) 
Fisher’s exact p-value Chr. Position SNP type Closest 
gene 
Distance 
to gene 
(kb) Cases 
(n=181) 
Controls 
(n=102) 
Genotypic Allelic 
rs359937 24.6 20.1 4.62x10
-6
 2.53x10
-1
 1 89982719 intergenic LRRC8B 7.2 
rs11627903 34.8 48.0 5.04x10
-6
 2.33x10
-3
 14 89484667 intergenic TRNAA17 39 
a
SNPs with genotypic p-values less than 10
-5
. 
bOrdered according to smallest to largest genotypic Fisher’s exact p-values. 
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Discussion 
  In our result, we initially identified 25 candidate copy-number deleted regions and 10 
duplicated regions that mostly enriched in the children of the preeclamptic mothers. Since the 
more common of the CNVs, the less possible they are associated with disease traits
28
, we 
confirmed the none uniqueness of the CNVs we detected through The Copy Number Variation 
Project (http://cnv.chop.edu) across healthy individuals, and the low to rare CNV frequencies in 
the general population through the Database of Genomic Variants 
(http://dgv.tcag.ca/dgv/app/home). Along the process of finding non-unique copy number 
variable regions, we found that most fetal CNVs were “copy number polymorphisms29” that 
might or might not have significant contributions to the preeclamptic mothers, and we ended up 
with 20 novel deletion candidates and 4 duplicated candidates. We decided to focus on deletions 
because loss of function of the protein products by homozygous or heterozygous deletions of 
certain genes are more frequent and severe than gains of function by slightly duplicated copies of 
the genes
26, 27
. The two fetal deleted regions we found most interesting on chromosome 1q21.2 
and 19q13.2 respectively contain annotated genes of ARNT (aryl hydrocarbon receptor nuclear 
translocator), CTSK (cathepsin K) and ACTN4 (alpha-actinin-4), that might have molecular and 
biological effects in developing preeclampsia in the mothers. We postulated the post-translational 
impairment of these protein functions due to copy number deletion.  
The functional transcription factor exists as a heterodimeric complex consisting of the aryl 
hydrocarbon receptor nuclear translocator (ARNT) and Hypoxia-inducible factor 1-alpha 
(HIF-1α)30. HIF-1α is a principal mediator of hypoxic adaptations, modulates through 
Wnt/β-catenin signaling in hypoxic status cells31. HIF-1α deletion has shown to impair 
hippocampal Wnt-dependent processes, including cell proliferation, differentiation and 
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functional maturation. A recent integrative transcriptome meta-analysis using fetal-derived 
histological subsections of placenta from multiple case-control preeclampsia studies pointed out 
that the genes clustered in the HIF-1α signaling pathway are dysregulated in the fetus of 
preeclamptic mothers
9
. This study also showed that the dominant genes involved in regulation of 
hopoxic trophoblast are HIF-1α, HIF-2α and ARNT. Another study also pointed out that hypoxia 
interferes with the differentiation of in vitro cultured cytotrophoblast into terminally 
differentiated syncytiotrophoblast, through DNA hypermythylation and suppression of associated 
genes
32
. The villi surfaced on syncytiotrophoblasts constitute the intervillous space which is 
resposible for maternal blood inflow and maternal-fetal exchange during pregnancy. Therefore, 
downregulated ARNT due to copy-number deletion might lead to unstable heterodimeric 
complex with HIF-1α, cuasing abnormal HIF-1α function in the fetus, thereby increase oxidative 
stress and provoke the risk of preeclampsia in the mother. CTSK mutation has been linked to a 
rare autosomal recessive disease pychodysotosis, which is characterized by osteosclerosis and 
short stature
33
. Moreover, co-culture of CTSK
+
 fibroblast with CTSK
-
 breast cancer cells has 
been found to enhance cancer cells invasion, and this enhanced invasive ability is blocked by 
CTSK inhibitors
34
. CTSK might thus have a putative role in regulating trophoblast invasion into 
maternal decidua, which is important in normal embryo implantation and the following process 
of vascular remodeling, maintaining stable plancetal blood inflows to the survival and growth of 
the fetus. CTSK downregulation might lead to defective trophoblast invasion and plancenta 
maldevelopment, whereas increase the possibility of ischemia in the fetus and preeclampsia in 
the mother. Mutation of ACTN4 has been linked to familial focal segmental glomerulosclerosis, 
which is a rare autosomal dominant disease characterized by increased urinary protein excretion 
and decreasing kidney function
35
. Reduced ACTN4 mRNA expression might dysregulate the 
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actin cytoskeleton of glomerular podocytes and increase protein filtration into urine. There are 
gradually growing statistical findings from large datasets or cohort studies pointing out the 
gene-environment interactions in the uterus between the fetus and the preeclamptic mother
6, 9, 13, 
36
, but there is still lack of direct biological and mechanistic evidence showing how the abnormal 
infant genes influence maternal health during pregnancy. Though nutrients and wastes exchange 
between the fetus and the mother, it is still unknown how extra protein excreted by the fetus into 
amniotic fluid would end up elevates proteinuria in the mother. We thus speculated about the 
possibility that the deleted fashion of ACTN4 in the infants might be passed down from the 
abnormality in the mothers, however, we didn’t find direct evidence in reviewing the data from 
our previous study
16
. 
In a further attempt to replicate our findings in the HAPO study (Figure 8), we didn’t discover 
matched deleted regions with those we found the most interesting regions containing ARNT, 
CTSK, and ACTN4 genes in the SOPHIA study. However, in the SOPHIA study, the deleted 
region upstream of ACTN4 gene that also resides in chromosome 19q13.2 contains a large part 
of RYR1 gene deletion (Figure 6). We not only found a match for it in the HAPO study, but also 
found a documented match that already linked fetal deletion to an association with preeclamptic 
mothers from an established preeclampsia gene database
37
. RYR1 is known as ryanodine 
receptor 1, which is part of the family of ryanodine receptors that form channels to transport 
positively charged calcium ions within cells
38
. One study compared mRNA and protein levels 
expressed by cultured primary syncytiotrophoblasts (the outer syncytial layer of the trophoblast 
that actively invades the uterine wall forming the outermost fetal component of the placenta) 
obtained from normal and preeclamptic mothers, and they found a significant decrease in 
calcium transport by the syncytiotrophoblast cultured from preeclamptic placentas and a 
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downregulation of RYR1 mRNA expression
39
. Based on systematic reviews of accumulated 
observational studies that found calcium supplementation may reduce the risk of preeclampsia 
and may help to prevent preterm birth
40, 41
, WHO also recommend on populations where calcium 
intake is low to take calcium supplementation as part of the antenatal care for the prevention of 
preeclampsia in pregnant women, particularly among those at higher risk of developing 
hypertension (http://www.who.int/elena/titles/calcium_pregnancy/en/). Fetal RYR1 gene deletion 
clearly plays a role in the development of preeclampsia in the mothers, which interferes with 
calcium transportation during trophoblast invasion that determines a successful pregnancy. 
Identification of this known preeclampsia associated RYR1 gene deletion in both SOPHIA and 
HAPO studies further attests the appropriateness of the procedure we preformed to generate 
prioritized candidate regions of CNVs in our study. 
Note that the strategy we implemented to determine targeted CNVs by odds ratio in the cases 
versus controls was completely subjective in our study; moreover, due to limited number of the 
study subjects, the CNV frequencies comparing cases to controls were usually low, which limited 
the power of our analyses, resulted in wide 95% confidence intervals (data not shown). 
  Genome-wide association study is a hypothesis-free approach that screens the entire genome 
for associations between genetic polymorphisms and a certain disease. The most important 
methodological issue with GWAS studies is multiple comparisons, which needs to be addressed 
by strictly statistical significance level correction and further replicative studies, and yet this 
corrected genome-wide significant level usually makes it difficult to find stringent result as can 
been seen in our study. The limitations of GWAS studies also includes the inability to detect 
associations between rare variants (prevalence < 2%) and the disease, where we assumed to be 
genotyping error and eliminated at the quality control step. We also excluded those SNPs at the 
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quality control step which violated of the Mendelian inheritance or Hardy-Weinberg equilibrium, 
where none in fact really existed
42, 43
 due to the intrinsic that allelic or genotypic frequencies in a 
population will remain constant from generation to generation in the absence of other sporadic 
evolutionary influences. In addition, GWAS only identifies a genomic location associated with 
the disease, but not proving a causal polymorphism, because GWA studies are unable to provide 
information on biological mechanisms underlying the association, which requires further 
molecular biology studies to fortify our understanding. 
Although our genome is born to be what it is, the difference between incidence case and 
prevalence case determined the genetic variations for incidences and survivors, which reflects 
divergent indications of the disease statuses. Recently the concept of endophenotypes, which 
involve multiple biological, behavioral or cognitive features to the vulnerability of a certain 
disorder
44
, might help explain the complex mechanisms contribute to preeclampsia. Since 
preeclampsia is defined by both gestational hypertension and proteinuria, these two traits might 
be determined by different genetic variations that are closely related to each other. For example, 
abnormality in the vasopressin gene might affect electrolytes metabolism, cause retention of 
sodium in the blood and elevation of blood volume and pressure
45
; insulin resistant 
predisposition might be related to diabetic and hypertensive traits; long-term stimulation of 
sympathetic nervous system by stress might contribute to hypertension as well; hypoxia and 
oxidative stress has been shown to interfere with placenta development by dysregulation of the 
EGFR growth factor signaling pathway to blood vessel defects in placenta
9
; although rare, 
genotype-phenotype defects in any of the components involved in glomerular filtration system 
can result in proteinuria
46
, etc. Although not every individual carrying certain genes will result in 
phenotypic expression, these people might still possess higher risk of preeclampsia during 
 26 
 
pregnancy. Moreover, in order to prevent population stratification, we only enrolled children 
from white mothers in our study, therefore the preeclamptic genetic variants across 
multi-ethnicity are left for further investigation. 
In conclusion, dysfunctional protein regulation in the fetus due to copy number deletion might 
or might not directly influence the mother. However, our study pointed out possible roles of 
ARNT, CTSK and ACTN4 gene deletions in the fetus that are associated with hypoxia 
modulation, postulated regulation of trophoblast invasion, and abnormal proteinuria in the fetus 
respectively, which need further biological experiments to substantiate the functional protein 
expression in associated with increased risk of preeclampsia in the mother. The long term goal of 
our study is to better understand the etiology of preeclampsia and in hopes to develop better 
screening tools based on genetic variants carried by the predisposed mother or fetus. With more 
thorough considerations of various genetic variations, including rare or common SNPs and 
CNVs, applying the concept of endophenotypes, and using integrative omics approaches, might 
one day help us decipher causal or etiological determinants among existing association studies, 
to more effectively intervene and prevent preeclampsia in susceptible individuals in a timely 
manner. 
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